Study detail
RecruitingPhase 2
A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition Factor (c-MET) Dysregulation
Abion Inc
Summary
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.
Description
This study will start with one cohort and it will be a parallel cohort expansion study.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No